Shares of Fresenius SE & Co. KGaA (OTCMKTS:FSNUY - Get Free Report) hit a new 52-week high during mid-day trading on Monday . The company traded as high as $12.70 and last traded at $12.70, with a volume of 35365 shares changing hands. The stock had previously closed at $12.32.
Analysts Set New Price Targets
Separately, Morgan Stanley restated an "overweight" rating on shares of Fresenius SE & Co. KGaA in a research report on Thursday, May 15th.
Get Our Latest Research Report on Fresenius SE & Co. KGaA
Fresenius SE & Co. KGaA Price Performance
The firm's 50-day moving average is $11.55 and its 200-day moving average is $10.24. The company has a market capitalization of $28.06 billion, a PE ratio of 66.11 and a beta of 0.78. The company has a quick ratio of 1.05, a current ratio of 1.36 and a debt-to-equity ratio of 0.57.
Fresenius SE & Co. KGaA (OTCMKTS:FSNUY - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The company reported $0.23 earnings per share for the quarter, topping the consensus estimate of $0.22 by $0.01. The business had revenue of $5.92 billion during the quarter, compared to the consensus estimate of $5.41 billion. Equities analysts predict that Fresenius SE & Co. KGaA will post 0.79 earnings per share for the current fiscal year.
Fresenius SE & Co. KGaA Increases Dividend
The firm also recently declared a dividend, which was paid on Wednesday, June 4th. Shareholders of record on Wednesday, May 28th were paid a $0.1827 dividend. The ex-dividend date was Tuesday, May 27th. This is an increase from Fresenius SE & Co. KGaA's previous dividend of $0.17. This represents a yield of 1.48%. Fresenius SE & Co. KGaA's payout ratio is currently 94.74%.
About Fresenius SE & Co. KGaA
(
Get Free Report)
Fresenius SE & Co KGaA, a health care company, provides products and services for chronically ill patients. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure.
Featured Articles
Before you consider Fresenius SE & Co. KGaA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fresenius SE & Co. KGaA wasn't on the list.
While Fresenius SE & Co. KGaA currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
